Rr7201a1 H
Rr7201a1 H
Rr7201a1 H
CONTENTS
Introduction.............................................................................................................1
Methods.....................................................................................................................5
Universal Screening Systematic Review and Review of
Evidence Summary.............................................................................................6
Cost-Effectiveness of Screening Strategies...................................................8
Universal Screening Summary of Findings...................................................9
Rationale for New Recommendations......................................................... 13
HBV Screening and Testing Recommendations....................................... 14
Recommendations and Guidance from Non-CDC Sources................. 19
Future Directions................................................................................................. 20
Conclusion............................................................................................................. 20
References.............................................................................................................. 20
The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and
Human Services, Atlanta, GA 30329-4027.
Suggested citation: [Author names; first three, then et al., if more than six.] [Title]. MMWR Suppl 2023;72(Suppl-#):[inclusive page numbers].
1Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC
Summary
Chronic hepatitis B virus (HBV) infection can lead to substantial morbidity and mortality. Although treatment is not considered
curative, antiviral treatment, monitoring, and liver cancer surveillance can reduce morbidity and mortality. Effective vaccines
to prevent hepatitis B are available. This report updates and expands CDC’s previously published Recommendations for
Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection (MMWR Recomm
Rep 2008;57[No. RR-8]) regarding screening for HBV infection in the United States. New recommendations include hepatitis B
screening using three laboratory tests at least once during a lifetime for adults aged ≥18 years. The report also expands risk-based
testing recommendations to include the following populations, activities, exposures, or conditions associated with increased risk for
HBV infection: persons incarcerated or formerly incarcerated in a jail, prison, or other detention setting; persons with a history
of sexually transmitted infections or multiple sex partners; and persons with a history of hepatitis C virus infection. In addition,
to provide increased access to testing, anyone who requests HBV testing should receive it, regardless of disclosure of risk, because
many persons might be reluctant to disclose stigmatizing risks.
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 1
Recommendations and Reports
after completion of a HepB vaccine series indicates identifying a person with HBV infection, testing for
immunity. Although certain persons might have anti-HBs HBeAg, anti-HBe, and HBV DNA can provide
of ≥10 mIU/mL after partial vaccination, whether this information on the level of viral replication and infectivity
confers long-term protection is unknown. Among vaccine and help guide clinical management.
responders who completed a vaccine series, anti-HBs can Background information on HBV, including virus
decline over time to levels of <10 mIU/mL; however, the description, transmission, clinical features, natural history,
majority are still immune and will mount an immune and HepB vaccination seroprotection and coverage, is available
response to a vaccine challenge ≥35 years after vaccination (Supplementary Appendix 1, https://stacks.cdc.gov/view/
(17–20). Hepatitis B immune globulin (HBIG) can cdc/124432).
provide anti-HBs for 4–6 months after administration;
therefore, testing for anti-HBs ≤6 months after HBIG Epidemiology and Risk Factors
administration is not an accurate measure of a person’s
immune status (21). Acute HBV Infection
• Total anti-HBc: Total anti-HBc develops in all HBV Of 3,192 acute HBV infection cases reported to CDC in 2019,
infections, resolved or current, and typically persists for an estimated 20,700 new infections (95% CI = 11,800–50,800)
life. Persons whose immunity to HBV is from a vaccine were identified after adjusting for underascertainment and
do not develop anti-HBc. Assays for total anti-HBc detect underreporting. During 2012–2019, the number of reported
both immunoglobulin M (IgM) and immunoglobulin G acute HBV infection cases in the United States remained
(IgG) antibodies to HBcAg; no test for IgG anti-HBc relatively stable (22,23).
alone is commercially available. During the typical course Geographic differences exist, with the highest rate of cases
of chronic infection, total anti-HBc and HBsAg will be (≥2.5 per 100,000 persons) in 2019 reported by Florida,
present, whereas IgM anti-HBc will disappear (Figure 1). Indiana, Kentucky, Maine, Ohio, Tennessee, and West Virginia
IgM anti-HBc should be ordered only when acute HBV (23). From 2011 to 2017, the percentage of acute HBV
infection is a concern. infections among women of childbearing age was stable
• Other markers (HBV DNA, HBeAg, and anti-HBe): nationally but increased in Alabama (from 0% to 0.3%),
HBV DNA is a measure of viral load. HBeAg is a marker Indiana (from 0% to 0.1%), and Kentucky (from 0.1% to
for viral replication and high infectivity; antibody to 0.2%) (24). Geographic differences in new infections might
HBeAg (anti-HBe) can be used to monitor response to be because of the opioid crisis; during 2006–2013, increases in
treatment and chronic HBV infection progression. After
* Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee
on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1):1–31.
† Susceptible persons include those who have never been infected with HBV (i.e., total anti-HBc negative) and either did not complete a HepB vaccine series per
Advisory Committee on Immunization Practices recommendations or who are known to be vaccine nonresponders.
2 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
incident cases of acute HBV infection in Kentucky, Tennessee, of the estimated 1.89 million persons (range = 1.49–2.40 million)
and West Virginia were among persons who reported IDU as chronically infected with HBV living in the United States,
a risk factor (25). 0.42 million (range = 0.28–0.67 million) were U.S. born
During 2019, the overall rate of reported acute infections and 1.47 million (95% CI = 1.21–1.73) were non-U.S. born
in the United States was 1.0 per 100,000 population. The (6,26). By region, the highest proportions of persons with
rate of reported acute HBV infections among persons aged chronic HBV infection in the United States were born in
0–19 years has remained at ≤0.1 case per 100,000 population East Asia, Southeast Asia, the Caribbean, South Central Asia,
since 2006, in part because of routine childhood vaccination and West Africa (6).
(23). However, transmission of HBV infection persists among From 2011 to 2017, the percentage of chronic HBV
adults, especially among older adults for whom vaccine uptake infection among women of childbearing age who were tested
is suboptimal. for HBV infection increased in Kentucky (from 0.2% to 0.4%),
Rates of acute HBV infection were higher among males Mississippi (from 0.2% to 0.4%), and West Virginia (from
(1.3 per 100,000 population) than females (0.7) and were 0.3% to 0.4%) (24). In 2019, the rate of newly reported cases
highest among not Hispanic or Latino (non-Hispanic) White of chronic HBV infection among adults varied by age, with
(1.0) persons and non-Hispanic Black persons (0.9). Among the highest rate (11.3 per 100,000 persons) reported among
the 1,780 case reports that included risk information for IDU, persons aged 30–39 years and the lowest rate (0.5) reported
35% reported IDU (23). Among the 1,042 case reports that among persons aged 0–19 years (23). During 2015–2017,
included sex partner data, 23% reported multiple sex partners. an estimated 20,678–21,314 infants were born to pregnant
Of the 2,009 case reports that included any risk information, women who were HBsAg positive (27). National Perinatal
47% had no risk identified. Hepatitis B Prevention Program data indicated that only half
(52.6%) of these infants were identified through prenatal
Chronic HBV Infection screening in 2017.
Data from the National Health and Nutrition Examination During 2019, a total of 1,662 deaths attributable to
Survey (NHANES) indicated an estimated 880,000 persons HBV infection in the United States were reported on death
were living with chronic HBV infection during 2013–2018 certificates, resulting in an age-adjusted rate of 0.42 per
(95% CI = 580,000–1,170,000) (5). The prevalence of resolved 100,000 persons (95% CI = 0.40–0.44) (23). The highest
HBV infection or HBV infection was 11.7 million persons death rates occurred among Asian and other Pacific Islander
(95% CI = 10.2–13.5 million). NHANES does not include persons (2.10), males (0.66), and persons aged 65–74 years
institutionalized populations and might underestimate the (1.54). However, deaths attributable to HBV infection have
prevalence among ethnic minority groups that are not well been found to be underreported on death certificates (1).
represented in the survey. In a 2018 meta-analysis of prevalence,
TABLE 1. Interpretation of screening test results for hepatitis B virus infection and recommended actions
Clinical state HBsAg Anti-HBs Total anti-HBc* IgM anti-HBc Action†
Acute infection Positive Negative Positive Positive Link to HBV infection care
Chronic infection Positive Negative Positive Negative§ Link to HBV infection care
Resolved infection Negative Positive Positive Negative Counsel about HBV infection reactivation risk
Immune (immunity inferred Negative Positive¶ Negative Negative Reassure if history of HepB vaccine series
from receipt of previous completion; if partially vaccinated, complete
vaccination) vaccine series per ACIP recommendations
Susceptible, never infected Negative Negative** Negative Negative Offer HepB vaccine per ACIP recommendations
Isolated core antibody positive†† Negative Negative Positive Negative Depends on cause of positive result
Abbreviations: ACIP = Advisory Committee on Immunization Practices; anti-HBs = antibody to hepatitis B surface antigen; HBcAg = hepatitis B core antigen;
HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HepB = hepatitis B; IgG = immunoglobulin G; IgM anti-HBc = immunoglobulin M antibodies to hepatitis B
core antigen; total anti-HBc = total antibody to hepatitis B core antigen.
* Total anti-HBc is a measure of both IgM and IgG antibodies to HBcAg.
† Source: Abara WE, Qaseem A, Schillie S, et al. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians
and the Centers for Disease Control and Prevention. Ann Intern Med 2017;167:794–804.
§ IgM anti-HBc also might be positive in persons with chronic infection during severe HBV infection flares or reactivation.
¶ Immune if anti-HBs concentration is >10 mIU/mL after vaccine series completion.
** Anti-HBs concentrations might wane over time among vaccine responders (Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection
in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67[No. RR-1]:1–31).
†† Can be the result of a past infection when anti-HBs levels have waned, occult infection, passive transfer of anti-HBc to an infant born to an HBsAg-positive gestational
parent, a false positive, or mutant HBsAg strain that is not detectable by laboratory assay.
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 3
Recommendations and Reports
FIGURE 1. Typical serologic courses of acute and chronic hepatitis B virus infection
HBsAg
Total anti-HBc
IgM anti-HBc
Anti-HBs
0 4 8 12 16 20 24 28 32 36 52 100
Weeks after exposure
HBsAg
Total anti-HBc
IgM anti-HBc
0 4 8 12 16 20 24 28 32 36 52
Weeks after exposure Years
Source: Adapted from Weinbaum CM, Williams I, Mast EE, et al.; CDC. Recommendations for identification and public health management of persons with chronic
hepatitis B virus infection. MMWR Recomm Rep 2008;57(No. RR-8):1–20.
Abbreviations: anti-HBc = antibody to hepatitis B core antigen; anti-HBe = antibody to hepatitis B e antigen; anti-HBs = antibody to hepatitis B surface antigen;
HBeAg = hepatitis B e antigen; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; IgM = immunoglobulin M.
4 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 5
Recommendations and Reports
6 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
conducted in the United States alone, the prevalence was The diagnostic accuracy of HBV tests has been evaluated
0.38% (range = 0%–0.74%) (Supplementary Table 11, https:// by the Food and Drug Administration (FDA) and was
stacks.cdc.gov/view/cdc/124432). Eight studies reported the not included as part of the systematic review. Any assay
prevalence of a history of infection (i.e., anti-HBc positive, HBsAg that receives FDA approval for clinical use must meet high
negative); the median was 6.2% (range = 4.8%–14.0%) (31–38). standards of diagnostic accuracy. A list of FDA-approved HBV
The ages of patients with chronic HBV infection (when serologic assays, including links to detailed information on
available) are included in the summary table (Supplementary their performance characteristics, is available (Supplementary
Table 11, https://stacks.cdc.gov/view/cdc/124432). No clear Table 21, https://stacks.cdc.gov/view/cdc/124432).
trends were identified in the prevalence of chronic HBV Q2b: What are the harms of hepatitis B screening?
infection by age across studies. Therefore, the work group
considered the economic analysis, vaccination rates and Data on harms in the systematic review were limited. In one
efficacy, the epidemiology of acute and chronic infections study, women with public insurance and who self-paid for
from surveillance data, ease of implementation, and harms of health care services were less likely to be screened, even though
missed identification of chronic infections in determining the HBsAg screening costs should have been covered; the authors
age thresholds for universal adult screening. hypothesized that out-of-pocket payments might be a barrier
Q1b: What is the yield (number of new diagnoses per to screening (45). In another study assessing acceptability
tests completed) and sensitivity of alternative of hepatitis screening among patients during colonoscopies,
HBV screening strategies (e.g., universal versus acceptance was 78% (46).
targeted screening or screening strategies based on Harms of screening for HBV would be expected to be
alternative risk factors)? similar to those for HCV. In a previous review, possible
harms of screening for hepatitis C were physical pain, anxiety,
As part of their HBV screening recommendations systematic cost, interpersonal problems related to learning infection
review, the U.S. Preventive Services Task Force (USPSTF) assessed status, stigma, time, fear, and reluctance to disclose illegal
the yield (number of new diagnoses per tests completed) and risk behaviors (47). Other plausible harms included concern
sensitivity of alternative HBV infection screening strategies (39). caused by false-positive results, distress resulting from lack of
USPSTF identified three fair quality, non-U.S.–based studies, education or understanding of resolved infection, insurability
which might limit applicability (40–42). On the basis of these and employment issues, and treatment adverse effects.
studies, the number of persons who need to be screened to identify The work group concluded that potential harms of screening
one HBV infection using risk-based strategies ranged from 32 to did not outweigh the benefits. In addition, universal screening
148. In comparison, fewer than 20 persons need to be screened to might reduce harms compared with risk-based screening by
identify a case of HCV infection using risk-based screening (43). not requiring persons to disclose potentially stigmatizing risk
Only one of the studies, conducted in France, assessed conditions (e.g., immigration status and IDU) to get tested.
CDC’s risk-based testing criteria (41). Using risk-based testing Q2c: What proportion of persons who screen positive for
had 100% sensitivity (i.e., 100% of infected persons were HBV infection are linked to care?
identified), and self-report identified 70% of persons with at
least one risk factor; however, the study population specifically Q2d: What proportion of persons who screen positive for
overrepresented persons at increased risk for infection. HBV infection are treatment eligible?
The work group also considered a prospective cohort study of
patients with cancer at one U.S. health center, where applying Q2e: What proportion of eligible persons who screen
CDC risk criteria to screening had 97% sensitivity (44). The positive for HBV infection are treated?
proportion of patients who met at least one risk criterion was 91%.
Therefore, in terms of provider time, universal screening might be Only two studies from the universal screening review
more efficient than risk-based testing. Because no studies directly reported on linkage to care. In a study among persons
assessed universal screening, the work group could not provide the attending free clinics, 69% of patients with a diagnosis of
yield of universal screening versus risk-based screening. chronic HBV infection enrolled in follow-up care (48).
Q2: How many additional persons would be linked In a free screening clinic, 78% of patients with HBV
to care? infection elected to undergo follow-up monitoring (i.e.,
alanine aminotransferase [ALT]) and HBV DNA), and 24%
Q2a: What is the diagnostic accuracy of HBV testing? (11 of 45) of those monitored were eligible for treatment
(i.e., viral load of >20,000 copies per mL) (49).
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 7
Recommendations and Reports
Data on treatment were only available in two studies of HBsAg positive, and 30% had a history of infection
antiviral treatment during chemotherapy. In one study, 23% (anti-HBc positive) (55). In 2019, surveillance data indicated
of patients at risk for reactivation were prescribed a preventive that 10% (92 of 899) of persons with acute cases had a sexual
nucleoside analog (50). In the other study, 12% (18 of 152) of contact and 2% (17 of 899) had a nonsexual household contact
patients with a previous HBV infection received antiviral drugs, (23). However, relying on self-reports of close contacts with
and 73% (11 of 15) of patients with chronic HBV infection HBV infection likely underestimates the risk. Global studies
received antiviral drugs (36). conducted during 1974–2007 found that 14%–60% of
To answer these key questions, the work group also assessed persons living in households with persons with chronic HBV
evidence from two additional studies that were not part of the infection have serologic evidence of resolved HBV infection,
systematic review but included the general population. In a and 3%–30% have chronic infection (14). Although screening
2008–2016 study of adults with chronic HBV infection and can prevent further spread of HBV infection, the work group
commercial insurance, 36% (6,004 of 16,644) of patients were was unable to estimate the size of that impact.
linked to care (defined as having had an ALT test and HBV Q4: Do desirable management and treatment effects
DNA or HBeAg test) (51). Of the patients with chronic HBV outweigh undesirable effects?
infection with prescription claims, 18% (2,926 of 16,572) were
treated. Among 2,338 patients with chronic HBV infection Key Q4 was not assessed by the systematic review because it
followed in a prospective cohort study, 78% had one or more has been reported elsewhere. USPSTF reviewed effectiveness
ALT tests annually, 37% had one or more HBV DNA tests of treatment on reducing viral load, HBeAg, HBsAg, cirrhosis,
annually, and 32% were treated (52). Not all patients with hepatocellular carcinoma (HCC), and death (39). Antiviral
chronic HBV infection require treatment; estimates of patients therapy was associated with viral suppression, HBsAg loss,
with HBV infection meeting AASLD criteria for treatment normalization of ALT levels, and HBeAg loss. Antiviral
range from 24% to 48% (53,54). These two studies did not therapy was associated with decreased risk for HCC and death
assess the proportion of persons treated among those who were compared with placebo or no therapy; however, data were
eligible. Overall, the work group found that linkage-to-care sparse and estimates imprecise. Therapy was not associated
rates ranged from 36% to 78%, and from 18% to 32% of with an increased risk for serious adverse events. The conclusion
patients with chronic HBV infection were prescribed treatment. of AASLD’s systematic review used in the development of
Q3: How many new infections of HBV would its treatment guidelines was that recommended treatment
be prevented? reduces cirrhosis, decompensated cirrhosis, HCC, and death
in adults with active chronic HBV infection and is strongly
Q3a: What proportion of close contacts are at risk recommended (10).
for infection?
The work group did not identify evidence directly assessing the Cost-Effectiveness
proportion of close contacts (excluding perinatal transmission)
who are at risk for infection and thus could not estimate the
of Screening Strategies
proportion of new infections that would be prevented by Universal Screening
universal adult screening. However, the work group found
A 2021 economic analysis on the cost-effectiveness of
evidence of the proportion of close contacts of persons with
one-time universal HBV screening of adults aged 18–69 years
HBV infection who themselves have HBV infection.
provided information for these guidelines (56). With an
From the systematic review, a cohort study of patients with
estimated prevalence of undiagnosed chronic HBV infection
cancer and previous HBV infection found that 8.1% reported
of 0.24%, universal HBsAg screening among adults
having a household contact with HBV infection (who was
aged 18–69 years was cost-saving compared with current
not a sex partner), and 15.2% reported sexual contact with
practice, assuming antiviral treatment drug costs remain at
a person with HBV infection. Of the patients with chronic
<$894 per year. Antiviral treatment drug costs would need to
HBV infection, 0.5% reported a nonsexual household contact
rise to $9,692 a year (approximately 19 times the cost at the
with HBV infection, and 1.5% reported sexual contact with a
time of the study) for universal screening to be no longer cost-
person with HBV infection (36).
effective. Undiagnosed prevalence was based on the NHANES
In a study of programs testing and linking patients with
estimate of 0.36% and the finding that 67% of persons with
hepatitis B to care in the United States, 14% of household
HBV infection were unaware of their infection (57). Current
contacts of persons who were HBsAg positive were themselves
8 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
practice was based on the literature and assumed that 33% of it identified persons with previous vaccination and averted the
persons with HBV infection were currently diagnosed, 36% cost of additional vaccine doses.
were linked to care, and 18% were receiving treatment (56).
Compared with current practice, universal screening would
be expected to avert an additional 7.4 cases of compensated Universal Screening Summary
cirrhosis, 3.3 cases of decompensated cirrhosis, 5.5 cases of
HCC, 1.9 liver transplants, and 10.3 HBV-related deaths per
of Findings
100,000 persons screened (56). Universal HBsAg screening The steering committee considered results of the systematic
of adults aged 18–69 years would save $262,857 per quality- review in conjunction with cost-effectiveness analyses,
adjusted life year (QALY) and would result in a gain of supplemental literature, practicality of implementing
135 QALYs per 100,000 adults screened. A probabilistic guidelines, public health benefits, subject matter expertise,
sensitivity analysis that varied all parameters in the model and reviewer and public feedback. Because of limited data,
simultaneously indicated a >99% likelihood that universal the steering committee was only indirectly able to assess
screening would be cost-effective compared with current the key question “How would adult universal screening for
practice at a maximum willingness-to-pay threshold of hepatitis B affect the number [and composition] of persons
$50,000 per QALY. who screen positive for HBV infection?” A summary of
Study authors conducted an unpublished analysis using the the evidence considered, rationale for screening (Box 2),
same methods as those in the economic analysis described in conclusions of the steering committee, and limitations is
this report, but with an upper age limit of 80 years instead available (Supplementary Table 10, https://stacks.cdc.gov/
of 69. They found one-time universal screening of adults aged view/cdc/124432). The steering committee concluded that
18–80 years with an HBsAg test would save $200,334 and simplifying the implementation of screening from a risk-
result in a gain of 128 QALYs per 100,000 adults screened. based to a universal approach might increase the number of
A sensitivity analysis found that using the triple panel persons aware of their infection. Overall, risk-based testing
(HBsAg, anti-HBc, anti-HBs) and assuming Medicare has been insufficient to identify persons with HBV infection
reimbursement of $28.27, universal screening with the in the United States and has been a barrier to appropriately
triple panel would be cost-effective, with an incremental screening populations with a disproportionate prevalence of
cost-effectiveness ratio of $11,207 per QALY (56). Using a disease. Assessment of risk is difficult for providers and might
cost-effectiveness threshold of $50,000 per QALY, universal be stigmatizing to the patient.
screening with the triple panel remained cost-effective if the A one-time HBV screening of adults would be complementary
HBV infection prevalence was >0.15%. A summary of the to the 2022 Advisory Committee on Immunization Practices
CHEERS checklist is available (Supplementary Table 20,
https://stacks.cdc.gov/view/cdc/124432). Minor deviations BOX 2. Rationale for universal hepatitis B virus screening
from the recommended standards were not considered a
• Hepatitis B virus (HBV) infection has substantial
substantial risk to quality.
morbidity and mortality.
• Chronic HBV infection can be detected before the
Screening in Higher Prevalence Settings development of severe liver disease using reliable and
A 2022 cost-effectiveness analysis evaluated whether inexpensive screening tests.
screening in STI clinics (i.e., a high-prevalence setting) with • Treatment for chronic HBV infection can reduce
universal vaccination can reduce costs and improve care (58). morbidity and mortality.
The researchers assumed the study population was aged • Management of chronic HBV infection might
18–69 years, had an estimated HBsAg prevalence of 4.2%, prevent transmission to others.
and had no previous HepB vaccination or known HBV • Universal screening of adults is cost-effective.
infection. One-time screening with the triple panel was cost- • Screening enables identification and management of
saving and prevented an additional 138 cases of cirrhosis, pregnant persons infected with HBV and their infants,
47 cases of decompensated cirrhosis, 90 cases of HCC, 33 which can reduce the risk for perinatal transmission.
liver transplants, and 163 HBV-related deaths per 100,000 • Screening can identify persons who are at risk for
adults screened. Even if chronic HBV infection prevalence in reactivation of HBV infection.
the STI clinic population was assumed to be zero, screening • Screening might identify persons who would benefit
plus vaccination was less costly than vaccination alone because from hepatitis B vaccination.
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 9
Recommendations and Reports
(ACIP) recommendation to vaccinate all adults aged risk for HBV reactivation was 24% (95% CI = 19%–30%)
19–59 years for HBV infection because screening establishes in patients with untreated chronic HBV infection and 1.4%
any history of infection, and vaccination protects from (95% CI = 0.8%–2.4%) in patients with resolved HBV
future infection and need for additional testing (59). The infection (72). The risk for HBV reactivation–related hepatitis
recommendations were supported by peer reviewers who are (i.e., symptomatic) was 9% (95% CI = 5%–16%) in patients
experts in the field as well as the majority of public comments. with chronic HBV infection; HBV reactivation–related
Patients with HBV infection have increased morbidity and hepatitis did not occur in patients with resolved infection.
mortality, and monitoring and treatment can improve health Three of 1,621 patients with chronic HBV infection had
outcomes. If more efficacious treatments are approved in the a major clinical event related to the reactivation (liver
future, this benefit will increase further. Although increasing decompensation or failure), but there were no deaths.
awareness of infection is expected to reduce transmission to Four studies (62,69,73,74) were published after the 2018
close contacts, this assumption is hypothetical because of the systematic review (72). In two national cohort studies of U.S.
lack of direct evidence. No studies directly compared universal veterans with chronic HCV infection prescribed DAA therapy,
screening with risk-based screening; therefore, the steering HBV reactivation was rare (<0.1%) and more frequent among
committee relied on the cost-effectiveness study finding that a patients who were HBsAg positive (62,73). Similarly, two other
one-time universal screen of adults is cost-effective and results U.S.-based cohort studies of patients with HCV coinfected
in improved health outcomes as compared with risk-based with HBV did not detect any cases of DAA-associated HBV
screening (56). reactivation (69,74).
Outcomes of HCV/HBV Coinfection
Persons with an Increased Risk for HBV In a study comparing patients with HCV infection
Infection Recommended for Testing achieving sustained virologic response to HCV treatment,
Persons with HCV Infection or anti-HBc positivity was identified as an independent risk
factor for the development of HCC (hazard ratio [HR] = 5.57;
a Past HCV Infection
95% CI = 1.45–21.39) (75). Conversely, a nested, case-
The systematic review found 8,295 articles for review; after control study of patients who were HBsAg negative with
title review, 1,233 potentially relevant articles remained. After HCV infection indicated that neither previous nor occult
review of articles meeting inclusion and exclusion criteria, HBV infection was associated with the development of
17 articles were included (Supplementary Table 12, https://stacks. HCC (76). Clinically significant hepatic events, including
cdc.gov/view/cdc/124432). In 10 U.S. studies, the prevalence of HBV reactivation, were more common among patients
current HBV infection (on the basis of HBsAg positivity, HBV who were cirrhotic than patients who were noncirrhotic
DNA positivity, or International Classification of Diseases, Tenth anti-HBc positive with chronic HCV infection undergoing
Revision codes) among persons with HCV infection ranged DAA therapy (73). Among a cohort of 51,781 veterans who
from 0.2% to 5.8% (median = 1.2%) (60–69). Among persons were HCV infected and who initiated DAA treatment, those
with HCV infection, the prevalence of ever being exposed to who were HBV/HCV coinfected (odds ratio [OR] = 2.25;
HBV ranged from 24.7% to 62.6% (median = 43.0%); this 95% CI = 1.17–4.31) and those with resolved HBV infection
finding was based on anti-HBc positivity, regardless of other (OR = 1.09; 95% CI = 1.03–1.15) were more likely to achieve
HBV test results (62–65,69,70). Isolated anti-HBc positivity sustained virologic response compared with patients who were
ranged from 36.9% to 53.8% (median = 39.5%) among HCV monoinfected (64).
patients with HCV infection (62,65,69). In a national cohort of 99,548 U.S. veterans, patients
HBV Reactivation During Direct-Acting Antiviral with HCV infection and documented HBV viremia
Therapy for HCV (HBV DNA detected) were at significantly higher risk for cirrhosis
(adjusted hazard ratio [aHR] = 1.89; 95% CI = 1.46–2.45),
FDA requires a boxed warning about the risk for HBV
HCC (aHR = 2.12; 95% CI = 1.26–3.60), and death
reactivation to be added to drug labels of direct-acting antiviral
(aHR = 1.62; 95% CI = 1.33–1.99) than patients who
(DAA) medication for HCV infection. The boxed warning
were HCV monoinfected, after controlling for demographic,
directs health care professionals to screen and monitor for
clinical, and antiviral treatment–related factors (68). In this
HBV infection in all patients receiving DAA treatment (71).
cohort, absence of HBV replication was associated with a
In a published systematic review of HBV reactivation during
clinical course similar to that of patients who were HCV
DAA therapy among patients with HCV infection, the overall
monoinfected. Compared with patients who were HCV
10 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
monoinfected, patients with HBV/HCV coinfection had more Three studies found an increased risk for HBV infection
advanced fibrosis, a faster fibrosis progression rate, and more associated with incarceration. In a study of blood donors,
severe steatosis (63). In a matched case-control study, patients persons detained ≥3 nights in a jail or detention facility had
with HBsAg-negative HCV infection with HCC were more three times higher odds of having serologic evidence of HBV
likely to have had previous HBV infection (anti-HBc positive), infection; however, the comparison group was not provided
regardless of anti-HBs status (anti-HBs negative [OR = 2.98; (p≤0.001) (86). In another study, persons incarcerated
95% CI = 2.12–5.08]; anti-HBs positive [OR = 1.84; >14 years had 1.68 (95% CI = 1.08–2.59) higher odds of ever
95% CI = 1.22–3.08]), compared with HCV-infected controls acquiring HBV infection compared with those incarcerated
without HCC (77). ≤7 years (81). Finally, a third study indicated that persons
Many studies had incomplete test data and used descriptive with any self-reported history of incarceration had increased
tests of significance rather than models that controlled for other odds (OR = 1.84; 95% CI = 1.02–3.31) of ever having
variables. The results from the MMAT quality assessment are HBV infection compared with persons with no history of
available (Supplementary Tables 18 and 19, https://stacks. incarceration (87).
cdc.gov/view/cdc/124432). The work group concluded that The work group determined that persons incarcerated or
because the prevalence estimate was ≥1% for HBV infection formerly incarcerated in a jail, prison, or other detention setting
and because of the boxed warning for DAAs, persons with should be considered at increased risk. This conclusion was
HCV infection or a past HCV infection should be considered based on the HBV infection prevalence estimate of ≥1% and
at increased risk for HBV infection. the studies directly indicating an association between HBV
infection and incarceration. The reasons for increased risk for
Persons Incarcerated or Formerly Incarcerated in HBV infection among persons who have been incarcerated
a Jail, Prison, or Other Detention Setting might include behaviors that occur before or during
The systematic review of HBV infection in correctional incarceration, including drug use, higher-risk sex, percutaneous
settings used for these testing guidelines was part of a larger exposures (e.g., tattooing), and structural factors that affect the
review that also contained articles on HCV infection in level of risk for these behaviors (e.g., availability of condoms,
correctional settings (“review 1”). The initial search of literature clean syringes, and engagement in health care). To ensure
on HBV infection and HCV infection in correctional settings all incarcerated persons receive recommended HBV testing,
yielded 2,395 unique articles for review; of these, 1,961 were correctional and detention facilities should consider offering
deemed irrelevant by title and abstract screening, resulting HBV screening at intake, periodic testing for susceptible
in 434 potential articles for review 1. A secondary abstract persons serving long-term sentences, and HepB vaccination
review (“review 2”), which applied the inclusion and exclusion for susceptible persons (16).
criteria for these guidelines, resulted in 57 articles that met
the inclusion criteria for full text review; three of these Persons with Sexually Transmitted Infections or
articles also were included in the HBV universal screening a History of Sexually Transmitted Infections or
systematic review. After full text review, 10 articles were Multiple Sex Partners
included (Supplementary Table 13, https://stacks.cdc.gov/ The work group used a published systematic review and
view/cdc/124432). The individual MMAT quality ratings are meta-analysis to assess risk among persons with a history
available (Supplementary Tables 16 and 17, https://stacks.cdc. of a non-HIV sexually transmitted infection (STI) (88).
gov/view/cdc/124432). This analysis of studies worldwide found positive and
Among eight studies, the prevalence of chronic HBV statistically significant associations between the prevalence
infection in persons with a history of incarceration ranged of HBV infection and other STIs. Three U.S. studies,
from 0.6% to 8.7% (median = 1.0%) (78–85). Two studies of published during 2008–2009, included four estimates of
men who were incarcerated assessed incidence, which ranged HBsAg prevalence among persons with syphilis or any STI;
from 2,700 to 3,579 infections per 100,000 persons per year the median prevalence was 1.6% (range = 0.9%–33.2%).
(78,81). One study reported 41 acute HBV infections acquired Among the four estimates, two were among groups with other
in prison; however, the total number tested was not reported risk factors for HBV infection (e.g., persons being processed
and therefore a prevalence or incidence rate could not be into jail and men who have sex with men [MSM]). Seven
calculated (85). Another study reported an infection rate of U.S. studies, published during 1998–2000, included nine
1.2% during an outbreak of HBV infection in a high-security estimates of prevalence of HBV infection or a history of HBV
correctional facility (83). infection (HBsAg or anti-HBc positive) among persons with
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 11
Recommendations and Reports
STIs or a history of STIs; the median prevalence was 22.4% Persons Who Use Injection Drugs or Have a
(range = 8.6%–83.5%). Among the nine estimates of past History of IDU
infection, four were among groups with other risk factors for
A systematic review estimated the prevalence of HBV
HBV infection (e.g., persons who use drugs, persons with HIV
infection among persons who use injection drugs to be 11.8%
infection, and MSM).
(range = 3.5%–20%) and ever having had an infection to be
A study of national surveillance reports and survey data during
22.6% (93). Transmission of HBV among persons who use
2013–2018 found 1,324 (38.2%) cases of sexually transmitted
injection drugs might be increasing. A study of prevalence of
acute HBV infection after excluding cases with a report of
anti-HBc in national survey data found an increase among
IDU; 5.3% of persons reported sexual contact with a person
persons who use injection drugs from 35.3% during 2001–
with HBV infection, 3.1% reported being male and having sex
2006 to 58.4% during 2013–2018 (94).
with another male partner, 27.8% reported having multiple sex
partners, and 2% reported a history of STI treatment 6 weeks Persons with HIV Infection
to 6 months before their HBV infection diagnosis (89). Cases Multiple studies with varying inclusion criteria and periods
were classified into mutually exclusive categories in the order during 1986–2012 used prospective cohort data from the
listed. The work group considered the HBsAg prevalence of U.S. Military HIV Natural History Study (NHS) to calculate
>1% among persons with an STI to be sufficient evidence of the prevalence of HBV infection among persons with HIV
increased risk. Although the recommendation for multiple infection. Among patients in NHS, coinfection ranged from
partners is not directly supported by the literature, it aligns 3.0% to 6.0% (95–97). In a large prospective cohort study
with AASLD recommendations to screen persons who are not of adults with HIV infection, annual chronic HBV infection
in a long-term, mutually monogamous relationship (i.e., more prevalence during 1996–2007 ranged from 7.8% to 8.6% (98).
than one sex partner during the previous 6 months) (11).
MSM
Infants Born to Pregnant Persons Who Are
Among a sample of Los Angeles County, California, residents
HBsAg Positive
from the National HIV Behavioral Surveillance system,
Without preventive steps, 90% of infants born to women 19% (95% CI = 15%–24%) of MSM had HBV infection
who are HBsAg and HBeAg positive and 5%–20% of infants or a history of HBV infection, and 35% of the sample were
born to women who are HBsAg positive, HBeAg negative will coinfected with HIV (99). In a survey of MSM from six U.S.
become infected (90–92). Additional information is available metropolitan areas during 1998–2000, the prevalence of ever
in Prevention of Hepatitis B Virus Infection in the United States: infection was 20.6%, and 2.3% of participants had active
Recommendations of the Advisory Committee on Immunization HBV infection; HBV infection was independently associated
Practices (15) and from AASLD (11). with a history of another STI, having more lifetime partners,
Persons Born in Regions with HBV Infection ever engaging in anal intercourse, and ever using injection
drugs (100).
Prevalence of ≥2%
A 2021 systematic review and meta-analysis estimated the Household, Needle-Sharing, or Sexual Contacts
prevalence of non-U.S.–born persons with chronic HBV of Persons with Known HBV Infection
infection in the United States to be 3.1% (95% CI = 2.5%–3.6%). HBV is highly infectious and can survive in the environment
Africa had the highest regional prevalence (8.6%), followed by for prolonged periods. Close (i.e., household, needle-sharing,
Asia (5.9%) and Oceania (4.5%) (6) (Box 3). or sexual) contacts of persons with known HBV infection are
Persons Born in the United States Not Vaccinated at greater risk (see Universal Screening Systematic Review and
Review of Evidence Summary).
as Infants Whose Parents Were Born in Regions
with HBV Infection Prevalence of ≥8% Persons on Dialysis, Hemodialysis, or
The population of persons born in the United States who Peritoneal Dialysis
were not vaccinated as infants whose parents were born in A study during 1997–2001 of adult hemodialysis patients
regions with HBV infection prevalence of ≥8% is at increased found an adjusted prevalence of HBV infection of 2.4%
risk for infection. The higher underlying prevalence in this (95% CI = 2.1–2.7) (101). Dialysis was reported only in 3%
population increases the likelihood of perinatal or close contact (34 of 1,292) of 2,019 acute HBV infection cases; however,
exposures (Box 3). the risk for developing chronic infection was higher among
12 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
• High prevalence (≥8%): Angola, Cabo Verde, Central African Republic, Chad, Eswatini, Ghana, Guinea,
Guinea-Bissau, Kiribati, Lesotho, Liberia, Mali, Mauritania, Niger, Nigeria, Philippines, Sao Tome and Principe,
Sierra Leone, Solomon Islands, Taiwan, Timor-Leste, Togo, Tonga, Turkmenistan, Tuvalu, and Zimbabwe.
• Intermediate prevalence (5%–7.9%): Albania, Benin, Burkina Faso, Cameroon, China, Côte d’Ivoire,
Democratic People’s Republic of Korea, Djibouti, Eritrea, Ethiopia, Federated States of Micronesia, Gabon, Indonesia,
Kyrgyzstan, Moldova, Mongolia, Mozambique, Myanmar, Papua New Guinea, Senegal, Somalia, South Sudan, Syria,
Tajikistan, Uzbekistan, Vanuatu, and Vietnam.
• Low–intermediate prevalence (2%–4.9%): Afghanistan, Azerbaijan, Bangladesh, Belarus, Bosnia and Herzegovina,
Bulgaria, Burundi, Cambodia, Comoros, Congo, Democratic Republic of Congo, Gambia, Georgia, Guyana, Haiti,
Hong Kong, India, Iraq, Jamaica, Jordan, Kazakhstan, South Korea, Laos, Madagascar, Malawi, Malaysia,
Marshall Islands, Oman, Pakistan, Romania, Rwanda, Samoa, Singapore, South Africa, Sri Lanka, Sudan, Tanzania,
Thailand, Trinidad and Tobago, Tunisia, Turkey, Uganda, Yemen, and Zambia.
• Low prevalence (≤1.9%): Algeria, Argentina, Armenia, Australia, Austria, Bahrain, Belgium, Belize, Bhutan, Bolivia,
Brazil, Canada, Chile, Colombia, Costa Rica, Croatia, Cuba, Czechia, Denmark, Dominican Republic, Ecuador, Egypt,
El Salvador, Estonia, Fiji, Finland, France, Germany, Greece, Guatemala, Honduras, Hungary, Iran, Ireland, Israel, Italy,
Japan, Kenya, Kosovo, Kuwait, Lebanon, Libya, Mexico, Morocco, Nepal, Netherlands, New Zealand, Nicaragua,
Norway, Palestine, Panama, Paraguay, Peru, Poland, Portugal, Qatar, Russia, Saudi Arabia, Slovakia, Slovenia, Spain,
Suriname, Sweden, Switzerland, Ukraine, United Arab Emirates, United Kingdom, United States, and Venezuela.
• Unknown prevalence (data not available): American Samoa, Andorra, Anguilla, Antigua and Barbuda, Aruba,
Bahamas, Barbados, Bermuda, Bonaire Sint Eustatius and Saba, Botswana, British Virgin Islands, Brunei,
Cayman Islands, Cook Islands, Curaçao, Cyprus, Dominica, Equatorial Guinea, Falkland Islands, Faroe Islands,
French Guiana, French Polynesia, Gibraltar, Greenland, Grenada, Guadeloupe, Guam, Holy See, Iceland, Isle of Man,
Latvia, Liechtenstein, Lithuania, Luxembourg, Macao, Macedonia, Maldives, Malta, Martinique, Mauritius, Mayotte,
Monaco, Montenegro, Montserrat, Namibia, Nauru, New Caledonia, Niue, Northern Mariana Islands, Palau,
Puerto Rico, Réunion, Saint Barthélemy, Saint Helena, Saint Kitts and Nevis, Saint Lucia, Saint Martin,
Saint Pierre and Miquelon, Saint Vincent and the Grenadines, San Marino, Serbia, Seychelles, Sint Maarten, Tokelau,
Turks and Caicos Islands, U.S. Virgin Islands, Uruguay, Wallis and Futuna, and Western Sahara.
Source: Polaris Observatory [Internet]. Lafayette, CO: Center for Disease Analysis Foundation; 2021. https://cdafound.org/polaris
persons who are immunosuppressed and undergoing dialysis Rationale for New Recommendations
than persons who are immunocompetent (23,102,103).
Recommendations for Preventing Transmission of Infections Chronic HBV infection can lead to substantial morbidity
Among Chronic Hemodialysis Patients includes testing and mortality but is detectable before the development of
recommendations for patients on hemodialysis (104). severe liver disease using reliable and inexpensive screening
tests. Routine monitoring and treatment for chronic HBV
Persons with Elevated ALT or Aspartate infection can reduce morbidity and mortality, supporting the
Aminotransferase Levels of Unknown Origin importance of early detection of HBV infection. In addition,
Persons with known chronic liver disease (e.g., cirrhosis, although not quantifiable, management of chronic infection
fatty liver disease, alcoholic liver disease, or autoimmune through prevention efforts can prevent further transmission
hepatitis) are not at increased risk for HBV infection unless to others. These recommendations consider a simpler and less
they have additional exposures or risk factors. However, persons stigmatizing implementation strategy than previous risk-based
with persistently elevated ALT or aspartate aminotransferase HBV screening recommendations. The recommendations also
(AST) levels without a known cause should be tested for HBV provide guidance that is complementary to the 2022 ACIP
infection as part of a medical evaluation of these abnormal recommendations to vaccinate all adults aged 19–59 years
laboratory values. against HBV infection (59) by providing a means to establish
immunity or any history of infection or the need for
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 13
Recommendations and Reports
vaccination to protect from future infection. Specific rationales at increased risk for exposure to HBV. “Testing” refers to
for recommendations are as follows: conducting serologic testing of persons with symptoms or who
• Universal screening: Universal screening of adults is cost- are identified to be at increased risk for exposure to HBV. The
effective compared with risk-based screening and averts following evidence-based recommendations for HBV screening
liver disease and death (56). Although a curative treatment update and expand those issued by CDC in 2008 (14).
is not yet available, early diagnosis and treatment of Screening is recommended for the following persons (Box 1):
chronic HBV infections reduces the risk for cirrhosis, liver • All adults aged ≥18 years at least once during a lifetime
cancer, and death (10,11). Risk-based testing alone has (new recommendation).
not identified most persons living with chronic HBV • All pregnant persons* during each pregnancy, preferably
infection and is considered inefficient for in the first trimester, regardless of vaccination status or
providers to implement. history of testing (15) (see Clinical Considerations).
• Triple panel screening: Using the triple panel (HBsAg, Testing is recommended for the following persons (Box 1):
anti-HBs, and total anti-HBc) is recommended for initial • Everyone with a history of risk for HBV infection,
screening because it can help identify persons who have regardless of age, if they might have been susceptible
an active HBV infection and could be linked to care, have during the period of risk (Box 4) (Figure 2). Susceptible
resolved infection and might be susceptible to reactivation persons include those who have never been infected with
(e.g., immunosuppressed persons), are susceptible and HBV (i.e., total anti-HBc negative) and either did not
need vaccination, or are vaccinated. When someone complete a HepB vaccine series per ACIP recommendations
receives triple panel screening, any future periodic testing or who are known vaccine nonresponders (15).
can use tests as appropriate (e.g., only HBsAg and anti- • Susceptible persons, regardless of age, with ongoing risk
HBc if the patient is unvaccinated). should be tested periodically, while risk persists (Figure 2)
• Adults aged ≥18 years: An “all adults” recommendation (see Clinical Considerations).
was considered more feasible to implement (e.g., for ű Offer testing if the risk for exposure occurred after
integrating into electronic medical record alerts) than one previous HBV serologic testing and while the person
among specific age groups. Considerations included the was susceptible.
favorable economic analysis across adult age groups, • Anyone who requests HBV testing. These persons should
similarly low vaccination rates among adult age groups, receive testing, regardless of disclosure of risk, because
comparable epidemiology of acute and chronic infections many persons might be reluctant to disclose stigmatizing
from surveillance data among age groups, and harms of risks (new recommendation).
missed identification of chronic infections. • Persons who have an increased risk for acquiring HBV
• Children and adolescents aged <18 years: Children and infection, including the following:
adolescents aged <18 years were not included in the ű Infants born to HBsAg-positive pregnant persons (15)
universal screening recommendation because of the low ű Persons born in regions with HBV infection prevalence
prevalence of HBV infection in this age group and high of ≥2% (Box 3)
levels of HepB vaccination. Children and adolescents aged ű U.S.-born persons not vaccinated as infants whose
<18 years who have risk factors and did not receive a parents were born in regions with HBV infection
complete vaccine series should be tested (Figure 2). prevalence of ≥8% (Box 3)
• New risk groups: The addition of three new risk groups ű Persons who are injecting drug users or have a history
systematic reviews was based on expert judgment, and the prison, or other detention setting (new recommendation)
work group recognizes other populations might also be at ű Persons with HIV infection
(new recommendation)
ű Men who have sex with men
14 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
FIGURE 2. Incorporating hepatitis B virus screening and testing into a clinic workflow, by age
A. Nonpregnant adults aged ≥18 years without a known history of HBV infection
No No
Yes Previously Had an activity, action
screened exposure, or
for HBV Yes condition
infection? associated with
increased risk Offer testing, if the exposure
since the last Yes occurred before vaccination
screening? (while susceptible) and after
the previous HBV test(s)
B. Children and adolescents aged 1–17 years without a known history of HBV infection
No Offer vaccine,
if susceptible
Has/had an
activity,
exposure, or
No/Unknown condition
Completed associated Offer testing,
HepB with increased if the exposure occurred
vaccine Yes while susceptible
risk since the
series last screening?
as an Offer vaccine,
infant? if susceptible
Yes No
action
Per ACIP guidelines, providers should only accept dated records as evidence of HepB vaccination. Previous screening for HBV infection should include
HBsAg, anti-HBc, and anti-HBs. After the collection of blood for serologic testing, persons who have not completed a vaccine series should be offered
vaccination per ACIP guidelines at the same visit. Susceptible persons have never been infected with HBV (i.e., total anti-HBc negative) and did not
complete a HepB vaccine series per ACIP recommendations.
Abbreviations: ACIP = Advisory Committee on Immunization Practices; anti-HBc = antibody to hepatitis B core antigen; anti-HBs = antibody to hepatitis B surface
antigen; HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; HepB = hepatitis B.
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 15
Recommendations and Reports
ű Persons with STIs or past STIs or multiple sex partners in this report to include a total anti-HBc test during universal
(new recommendation) (see Clinical Considerations) adult screening will support identification of persons with
ű Household contacts or former household contacts of past HBV infection who should be aware of their risk for
persons with known HBV infection reactivation in the context of immunosuppression.
ű Needle-sharing or sexual contacts of persons with known
16 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
BOX 4. Persons and activities, exposures, or conditions associated for acute HBV infection is not typically indicated except among
with an increased risk for hepatitis B virus infection — CDC testing patients with severe disease (11).
recommendations, 2023
Persons who receive a diagnosis of chronic HBV infection
• Infants born to pregnant persons who are hepatitis B can benefit from monitoring and counseling, including
surface antigen positive mental health support (111). CDC treatment guidelines
• Persons born in regions with hepatitis B virus (HBV) have not been developed and are beyond the scope of these
infection prevalence of ≥2% screening guidelines. However, AASLD has guidance for the
• U.S.-born persons not vaccinated as infants whose monitoring and treatment of chronic HBV infection (11).
parents were born in regions with HBV infection Simplified guidance for primary care medical providers or
prevalence of ≥8% other nonspecialists is available from the Hepatitis B Primary
• Injection drug use Care Workgroup (Table 2) (112).
• Incarceration in a jail, prison, or other detention All patients who test positive for active HBV infection should
setting (new recommendation) be provided information on how to prevent transmission to
• HIV infection others (Box 5). Notification, testing, and vaccination of their
• Hepatitis C virus infection (new recommendation) household contacts or former household contacts, sex partners,
• Men who have sex with men and needle-sharing contacts are recommended, as appropriate.
• Sexually transmitted infections or multiple sex As resources allow, viral hepatitis or STI programs within local
partners (new recommendation) or state health departments might be available to support
• Household contacts of persons with known providers with contact tracing and notification.
HBV infection Persons living with HBV infection have rights protected
• Needle-sharing or sexual contacts of persons with under the Americans with Disabilities Act (113). Persons
known HBV infection should not be excluded from practicing in the health care field
• Maintenance dialysis, including in-center or home or from school, play, child care, work, or other settings because
hemodialysis and peritoneal dialysis of their HBV infection (114,115).
• Elevated alanine aminotransferase or aspartate
Persons with Resolved (Past) HBV Infection
aminotransferase levels of unknown origin
• Persons who request HBV testing Patients should be counseled about their history of HBV
(new recommendation) infection and risk for reactivation. Therapies with the highest
TABLE 2. Initial medical evaluation of persons who are hepatitis B surface antigen positive
History/Examination Patient education Routine laboratory tests Serology/Virology Imaging/Staging studies
• Symptoms/signs of cirrhosis • Educate patients on how to • CBC • HBeAg/anti-HBe • Abdominal ultrasound with or
• Alcohol screening and prevent transmission to others • Comprehensive metabolic panel, • HBV DNA without AFP§
brief intervention • Identify household contacts, including AST/ALT, total bilirubin, • Anti-HAV (total or IgG) to • Elastography (e.g., FibroScan)
• Metabolic risk factors sex partners, or needle-sharing alkaline phosphatase, albumin, determine need for or serum fibrosis assessment
• Family history of contacts for screening and creatinine, and INR vaccination if none (e.g., APRI, FibroSure, FIB-4)
hepatocellular carcinoma vaccination documented
• Hepatitis A vaccination status; • Recommend abstinence or • Anti-HCV
offer vaccine if unvaccinated limited use of alcohol* • Anti-HDV†
• Recommend steps to reduce risk • Anti-HIV
for metabolic syndrome and • Other STIs (as indicated)
fatty liver
• Refer to harm reduction
counseling or drug treatment
services, as needed
Source: Table adapted from Tang AS, Thornton K; Hepatitis B Primary Care Workgroup. Hepatitis B management: guidance for the primary care provider. Seattle, WA:
University of Washington National Hepatitis Training Center; 2020.
Abbreviations: AFP = alpha fetoprotein; anti-HAV = antibody to hepatitis A virus; anti-HBe = antibody to hepatitis B e antigen; anti-HCV = antibody to hepatitis C virus;
anti-HDV = antibody to hepatitis D virus; APRI = AST to platelet ratio index; AST/ALT = aspartate aminotransferase/alanine aminotransferase; CBC = complete blood
count; HBeAg = hepatitis B e antigen; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; INR = international normalized ratio; STI = sexually transmitted infection.
* More than seven alcoholic drinks/week for women and more than 14 drinks/week for men is associated with increased risk for liver disease (Source: Terrault NA, Lok
ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560–99).
† Source: AASLD Practice Guidelines (https://www.aasld.org/practice-guidelines).
§ Ultrasound for hepatocellular carcinoma surveillance has higher diagnostic accuracy than AFP; therefore, AFP alone is not recommended except when ultrasound
is unavailable or unaffordable (Source: Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018
hepatitis B guidance. Hepatology 2018;67:1560–99).
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 17
Recommendations and Reports
• To prevent or reduce risk for transmission to others, persons who are hepatitis B surface antigen (HBsAg) positive should
take the following actions:
ű Notify their household, sexual, and needle-sharing contacts that they should be tested for markers of hepatitis B virus
(HBV) infection; if susceptible, contacts should complete the hepatitis B (HepB) vaccine series
ű Use condoms to protect susceptible sex partners from acquiring HBV infection from sexual activity until the sex
partners can be vaccinated and their immunity documented (condoms and other prevention methods can also reduce
risks for other sexually transmitted infections
ű Cover cuts and skin lesions to prevent spread of infectious secretions or blood
ű Clean blood spills with bleach solution*
ű Refrain from donating blood, plasma, tissue, or semen
ű Refrain from sharing household articles (e.g., toothbrushes and razors) that could become contaminated with blood
ű Refrain from sharing needles, syringes, and other injection equipment
ű Dispose of blood, body fluids, and medical waste properly
• Newborns of pregnant persons who are HBsAg positive should receive the HepB vaccine and HepB immune globulin at
birth and complete the HepB vaccine series according to the recommended vaccination schedule.†
• When seeking medical or dental care, persons who are HBsAg positive should tell those responsible for their care of their
HBsAg status so they can be evaluated and managed appropriately.
* Source: Rutala WA, Weber DJ; Healthcare Infection Control Practices Advisory Committee. Guideline for disinfection and sterilization in healthcare facilities,
2008. Atlanta, GA: US Department of Health and Human Services, CDC; 2008. https://stacks.cdc.gov/view/cdc/47378
† Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on
Immunization Practices. MMWR Recomm Rep 2018;67:(No. RR-1):1–31.
risk for reactivation include B-cell depleting agents (e.g., persons who have initiated, but not completed, the HepB
rituximab and ofatumumab). American Society of Clinical vaccine series, regardless of anti-HBs status. HepB vaccine
Oncology and AASLD guidelines have more information series completion is important for long-term immunogenicity.
on therapies and conditions associated with increased risk Persons who are susceptible, refuse vaccination, and are at
for reactivation, as well as recommendations for treatment increased risk for HBV infection should be periodically tested.
(11,109,116,117). Antiviral therapy for HBV infection, when Frequency of periodic testing should be a shared decision
initiated before immunosuppressive or cytotoxic therapy, between the patient and provider and be based on individual
can prevent reactivation of disease (118). The systematic risk factors and immune status.
review indicated the prevalence of resolved HBV infection
(i.e., HBsAg negative and anti-HBc positive) in the general Persons Who Are Fully Vaccinated
population ranges from 4.8% to 14.0% (median = 6.2%). Against HBV Infection
Notification, testing, and vaccination of household, sex partners, Persons are considered fully vaccinated if they have
and needle-sharing contacts of patients with HBV infection or completed a HepB vaccine series and can be reassured about
a history of HBV infection are recommended, as appropriate. protection against future illness. Vaccination status should
be clearly documented in the medical record. Anti-HBs
Persons Who Are Susceptible to HBV Infection concentrations can wane over time among vaccine responders
Persons who are susceptible to HBV infection should be (20). For persons with a clearly documented vaccination series
told that they have never been infected with HBV and are who test negative for anti-HBs, refer to Prevention of Hepatitis B
not protected from future infection. All persons who are Virus Infection in the United States: Recommendations of the
susceptible to infection should be offered HepB vaccine per Advisory Committee on Immunization Practices for specific
ACIP recommendations (59). Anti-HBs concentrations can populations for whom revaccination might be recommended
wane over time among vaccine responders. For persons with (e.g., patients on hemodialysis) (15). Revaccination or booster
a clearly documented vaccination series who test negative for doses are not routinely recommended for persons who are
anti-HBs, refer to Prevention of Hepatitis B Virus Infection in immunocompetent (15).
the United States: Recommendations of the Advisory Committee
on Immunization Practices (15). Vaccine should be offered to
18 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 19
Recommendations and Reports
Conflicts of Interest
Future Directions All authors have completed and submitted the International
CDC will review these recommendations as new treatments, Committee of Medical Journal Editors form for disclosure of
tests, epidemiology, HepB vaccination rates, and experience potential conflicts of interest. No potential conflicts of interest
gained from implementation of these recommendations become were reported.
available; recommendations will be revised as needed. The work References
group did not conduct a systematic review to reassess any of
1. Bixler D, Zhong Y, Ly KN, et al.; CHeCS Investigators. Mortality among
the groups at increased risk for HBV infection from the 2008 patients with chronic hepatitis B infection: the Chronic Hepatitis Cohort
guidelines; future recommendations might modify the groups Study (CHeCS). Clin Infect Dis 2019;68:956–63. PMID:30060032
recommended for periodic testing. Additional data on the ideal https://doi.org/10.1093/cid/ciy598
2. Montuclard C, Hamza S, Rollot F, et al. Causes of death in people with
frequency of periodic testing is needed. Continued collaboration chronic HBV infection: a population-based cohort study. J Hepatol
with laboratories to bundle the three HBV tests (HBsAg, anti- 2015;62:1265–71. PMID:25625233 https://doi.org/10.1016/j.
HBs, and anti-HBc) would facilitate ordering the tests together jhep.2015.01.020
3. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma
as a triple panel. In addition, reporting a triple panel summary and hepatitis B virus. A prospective study of 22 707 men in Taiwan.
result will aid providers in correctly interpreting results. Finally, Lancet 1981;2:1129–33. PMID:6118576 https://doi.org/10.1016/
a better understanding of the prevalence of HDV in the United S0140-6736(81)90585-7
States is needed to inform recommendations for HDV screening 4. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP.
Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface
among persons with HBV infection. antigen-positive Alaska Native carriers. Arch Intern Med 1990;150:1051–4.
P M I D : 2 1 5 8 7 7 3 h t t p s : / / d o i . o r g / 1 0 . 1 0 0 1 / a rc h i n t e . 1 9 9 0 .
00390170087019
Conclusion 5. Roberts H, Ly KN, Yin S, Hughes E, Teshale E, Jiles R. Prevalence
of hepatitis B virus (HBV) infection, vaccine-induced immunity, and
Universal screening of adults for HBV infection is cost- susceptibility among at-risk populations: U.S. households, 2013–
2018. Hepatology 2021;74:2353–65. PMID:34097776 https://doi.
effective compared with risk-based screening and averts liver org/10.1002/hep.31991
disease and death (56). Although a curative treatment is not 6. Wong RJ, Brosgart CL, Welch S, et al. An updated assessment of chronic
yet available, early diagnosis and treatment of chronic HBV hepatitis B prevalence among foreign-born persons living in the United
States. Hepatology 2021;74:607–26. PMID:33655536 https://doi.
infections reduces the risk for cirrhosis, liver cancer, and death org/10.1002/hep.31782
(10,11). Risk-based testing alone has not identified most 7. American Community Survey 1-Year Public Use Microdata Sample
persons living with chronic HBV infection and is inefficient (PUMS) 2018. Variables: place of birth and decade of entry. Washington,
for providers to implement. Along with vaccination strategies, DC: US Department of Labor, Census Bureau; 2019. https://www.
census.gov/programs-surveys/acs/microdata/access.2018.html
universal screening of adults and appropriate testing of persons 8. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus
at increased risk for HBV infection will improve health infection: relation of age to the clinical expression of disease and subsequent
outcomes, reduce the prevalence of HBV infection in the development of the carrier state. J Infect Dis 1985;151:599–603.
PMID:3973412 https://doi.org/10.1093/infdis/151.4.599
United States, and advance viral hepatitis elimination goals.
20 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
9. Lu P-J, Hung M-C, Srivastav A, et al. Surveillance of vaccination coverage 25. Harris AM, Iqbal K, Schillie S, et al. Increases in acute hepatitis B virus
among adult populations—United States, 2018. MMWR Surveill Summ infections—Kentucky, Tennessee, and West Virginia, 2006–2013.
2021;70(No. SS-3):1–26. PMID:33983910 https://doi.org/10.15585/ MMWR Morb Mortal Wkly Rep 2016;65:47–50. PMID:26821369
mmwr.ss7003a1 https://doi.org/10.15585/mmwr.mm6503a2
10. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, 26. Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM.
Murad MH; American Association for the Study of Liver Diseases. Prevalence of chronic hepatitis B virus infection in the United States.
AASLD guidelines for treatment of chronic hepatitis B. Hepatology Am J Gastroenterol 2020;115:1429–38. PMID:32483003 https://doi.
2016;63:261–83. PMID:26566064 https://doi.org/10.1002/hep.28156 org/10.14309/ajg.0000000000000651
11. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, 27. Koneru A, Fenlon N, Schillie S, Williams C, Weng MK, Nelson N.
diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B National Perinatal Hepatitis B Prevention Program: 2009–2017.
guidance. Hepatology 2018;67:1560–99. PMID:29405329 https://doi. Pediatrics 2021;147:e20201823. PMID:33531336 https://doi.
org/10.1002/hep.29800 org/10.1542/peds.2020-1823
12. U.S. Department of Health and Human Services. Viral hepatitis 28. Carande-Kulis V, Elder RW, Koffman DM. Standards required for
national strategic plan for the United States: a roadmap to elimination the development of CDC evidence-based guidelines. MMWR Suppl
(2021–2025). Washington, DC: US Department of Health and Human 2022;71(Suppl-1):1–6. PMID:35025853 https://doi.org/10.15585/
Services; 2020. https://www.hhs.gov/sites/default/files/Viral-Hepatitis- mmwr.su7101a1
National-Strategic-Plan-2021-2025.pdf 29. Hong QN, Pluye P, Fàbregues S, et al. Improving the content validity
13. World Health Organization. Global health sector strategies on, of the mixed methods appraisal tool: a modified e-Delphi study.
respectively, HIV, viral hepatitis and sexually transmitted infections J Clin Epidemiol 2019;111:49–59.e1. PMID:30905698 https://doi.
for the period 2022–2030. Geneva, Switzerland: World Health org/10.1016/j.jclinepi.2019.03.008
Organization; 2022. https://cdn.who.int/media/docs/default-source/ 30. Husereau D, Drummond M, Petrou S, et al.; CHEERS Task Force.
hq-hiv-hepatitis-and-stis-library/full-final-who-ghss-hiv-vh-sti_1- Consolidated Health Economic Evaluation Reporting Standards
june2022.pdf?sfvrsn=7c074b36_1 (CHEERS) statement. Int J Technol Assess Health Care 2013;29:117–22.
14. Weinbaum CM, Williams I, Mast EE, et al.; CDC. Recommendations PMID:23587340 https://doi.org/10.1017/S0266462313000160
for identification and public health management of persons 31. Abara WE, Collier MG, Moorman A, et al. Characteristics of deceased
with chronic hepatitis B virus infection. MMWR Recomm Rep solid organ donors and screening results for hepatitis B, C, and human
2008;57(No. RR-8):1–20. PMID:18802412 immunodeficiency viruses—United States, 2010–2017. MMWR
15. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B Morb Mortal Wkly Rep 2019;68:61–6. PMID:30677008 https://doi.
virus infection in the United States: recommendations of the Advisory org/10.15585/mmwr.mm6803a2
Committee on Immunization Practices. MMWR Recomm Rep 32. Mortensen E, Kamali A, Schirmer PL, et al. Are current screening
2018;67(No. RR-1):1–31. PMID:29939980 https://doi.org/10.15585/ protocols for chronic hepatitis B virus infection adequate? Diagn
mmwr.rr6701a1 Microbiol Infect Dis 2016;85:159–67. PMID:27009896 https://doi.
16. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. org/10.1016/j.diagmicrobio.2015.12.005
Recommendations of the Advisory Committee on Immunization 33. Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic
Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR hepatitis B virus (HBV) infection in U.S. households: National Health
Morb Mortal Wkly Rep 2018;67:455–8. PMID:29672472 https://doi. and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology
org/10.15585/mmwr.mm6715a5 2016;63:388–97. PMID:26251317 https://doi.org/10.1002/hep.28109
17. Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection 34. Seamon MJ, Ginwalla R, Kulp H, et al. HIV and hepatitis in an urban
after hepatitis B vaccine: results of a 30-year follow-up study and response penetrating trauma population: unrecognized and untreated. J Trauma
to a booster dose. J Infect Dis 2016;214:16–22. PMID:26802139 2011;71:306–10, discussion 311. PMID:21825931 https://doi.
https://doi.org/10.1093/infdis/jiv748 org/10.1097/TA.0b013e31822178bd
18. Leuridan E, Van Damme P. Hepatitis B and the need for a booster 35. Levy V, Yuan J, Ruiz J, et al. Hepatitis B sero-prevalence and risk
dose. Clin Infect Dis 2011;53:68–75. PMID:21653306 https://doi. behaviors among immigrant men in a population-based household survey
org/10.1093/cid/cir270 in low-income neighborhoods of northern California. J Immigr Minor
19. Middleman AB, Baker CJ, Kozinetz CA, et al. Duration of protection Health 2010;12:828–33. PMID:19319680 https://doi.org/10.1007/
after infant hepatitis B vaccination series. Pediatrics 2014;133:e1500–7. s10903-009-9239-6
PMID:24843060 https://doi.org/10.1542/peds.2013-2940 36. Ramsey SD, Unger JM, Baker LH, et al. Prevalence of hepatitis B
20. Bruce MG, Bruden D, Hurlburt D, et al. Protection and antibody levels virus, hepatitis C virus, and HIV infection among patients with
35 years after primary series with hepatitis B vaccine and response to a newly diagnosed cancer from academic and community oncology
booster dose. Hepatology 2022;76:1180–9. PMID:35320592 https:// practices. JAMA Oncol 2019;5:497–505. PMID:30653226 https://
doi.org/10.1002/hep.32474 doi.org/10.1001/jamaoncol.2018.6437
21. Scheiermann N, Kuwert EK. Uptake and elimination of hepatitis B 37. Thompson LA, Heath LJ, Freml H, Delate T. Universal hepatitis B screening
immunoglobulins after intramuscular application in man. Dev Biol and management in patients with cancer who received immunosuppressive
Stand 1983;54:347–55. PMID:6653890 chemotherapy. J Oncol Pharm Pract 2020;26:1141–6. PMID:31789111
22. Klevens RM, Liu S, Roberts H, Jiles RB, Holmberg SD. Estimating acute https://doi.org/10.1177/1078155219889116
viral hepatitis infections from nationally reported cases. Am J Public 38. Beste LA, Ioannou GN, Chang MF, et al. Prevalence of hepatitis B
Health 2014;104:482–7. PMID:24432918 https://doi.org/10.2105/ virus exposure in the Veterans Health Administration and association
AJPH.2013.301601 with military-related risk factors. Clin Gastroenterol Hepatol
23. CDC. Viral hepatitis surveillance—United States, 2019. Atlanta, GA: 2020;18:954–962.e6. PMID:31394284 https://doi.org/10.1016/j.
US Department of Health and Human Services, CDC; 2021. https:// cgh.2019.07.056
www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm 39. Chou R, Blazina I, Bougatsos C, et al. Screening for hepatitis B virus
24. Kushner T, Chen Z, Tressler S, Kaufman H, Feinberg J, Terrault NA. infection in nonpregnant adolescents and adults: updated evidence
Trends in hepatitis B infection and immunity among women of report and systematic review for the U.S. Preventive Services Task Force.
childbearing age in the United States. Clin Infect Dis 2020;71:586–92. JAMA 2020;324:2423–36. PMID:33320229 https://doi.org/10.1001/
PMID:31504302 https://doi.org/10.1093/cid/ciz841 jama.2020.19750
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 21
Recommendations and Reports
40. Spenatto N, Boulinguez S, Mularczyk M, et al. Hepatitis B screening: 55. Harris AM, Link-Gelles R, Kim K, et al. Community-based services to
who to target? A French sexually transmitted infection clinic experience. improve testing and linkage to care among non-US–born persons with
J Hepatol 2013;58:690–7. PMID:23220369 https://doi.org/10.1016/j. chronic hepatitis B virus infection—three US programs, October 2014–
jhep.2012.11.044 September 2017. MMWR Morb Mortal Wkly Rep 2018;67:541–6.
41. Bottero J, Boyd A, Lemoine M, et al. Current state of and needs for PMID:29771873 https://doi.org/10.15585/mmwr.mm6719a2
hepatitis B screening: results of a large screening study in a low-prevalent, 56. Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-
metropolitan region. PLoS One 2014;9:e92266. PMID:24663387 effectiveness of one-time universal screening for chronic hepatitis B
https://doi.org/10.1371/journal.pone.0092266 infection in adults in the United States. Clin Infect Dis 2022;74:210–7.
42. Wolffram I, Petroff D, Bätz O, et al.; German Check-Up 35+ Study PMID:33956937 https://doi.org/10.1093/cid/ciab405
Group. Prevalence of elevated ALT values, HBsAg, and anti-HCV in 57. Patel EU, Thio CL, Boon D, Thomas DL, Tobian AAR. Prevalence
the primary care setting and evaluation of guideline defined hepatitis of hepatitis B and hepatitis D virus infections in the United States,
risk scenarios. J Hepatol 2015;62:1256–64. PMID:25617500 https:// 2011–2016. Clin Infect Dis 2019;69:709–12. PMID:30605508 https://
doi.org/10.1016/j.jhep.2015.01.011 doi.org/10.1093/cid/ciz001
43. Moyer VA; US Preventive Services Task Force. Screening for hepatitis C virus 58. Hutton DW, Toy M, Salomon JA, et al. Cost-effectiveness of hepatitis B
infection in adults: U.S. Preventive Services Task Force recommendation testing and vaccination of adults seeking care for sexually transmitted
statement. Ann Intern Med 2013;159:349–57. PMID:23798026 infections. Sex Transm Dis 2022;49:517–25. PMID:35312661 https://
https://doi.org/10.7326/0003-4819-159-5-201309030-00672 doi.org/10.1097/OLQ.0000000000001632
44. Hwang JP, Lok AS, Fisch MJ, et al. Models to predict hepatitis B virus 59. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination
infection among patients with cancer undergoing systemic anticancer in adults aged 19–59 years: updated recommendations of the Advisory
therapy: a prospective cohort study. J Clin Oncol 2018;36:959–67. Committee on Immunization Practices—United States, 2022. MMWR
Erratum in: J Clin Oncol 2020;38:2599. PMID:29447061 https://doi. Morb Mortal Wkly Rep 2022;71:477–83. PMID:35358162 https://doi.
org/10.1200/JCO.2017.75.6387 org/10.15585/mmwr.mm7113a1
45. Abara WE, Cha S, Malik T, et al. Prenatal screening for and prevalence 60. Abutaleb A, Almario JA, Alghsoon S, et al. Higher levels of fibrosis
of hepatitis B surface antigen in pregnant women and prevention of in a cohort of veterans with chronic viral hepatitis are associated
transmission to infants born to infected mothers—Guam, 2014. J with extrahepatic cancers. J Clin Exp Hepatol 2021;11:195–200.
Pediatric Infect Dis Soc 2018;7:290–5. PMID:28992071 https://doi. PMID:33746444 https://doi.org/10.1016/j.jceh.2020.08.001
org/10.1093/jpids/pix062 61. Armed Forces Health Surveillance Center (AFHSC). Viral hepatitis B,
46. Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort active component, U.S. Armed Forces, 2000–2010. MSMR 2011;18:5–9.
screening for chronic hepatitis during colonoscopy appointments. PMID:21879785
Am J Gastroenterol 2013;108:981–9. PMID:23511461 https://doi. 62. Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of
org/10.1038/ajg.2013.50 hepatitis B reactivation among 62,920 veterans treated with oral
47. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC hepatitis C antivirals. Hepatology 2017;66:27–36. PMID:28240789
recommendations for hepatitis C screening among adults—United https://doi.org/10.1002/hep.29135
States, 2020. MMWR Recomm Rep 2020;69(No. RR-4):1–17. 63. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American
PMID:32271723 https://doi.org/10.15585/mmwr.rr6902a1 patients with chronic hepatitis C virus infection: prevalence, racial/
48. Bailey MB, Shiau R, Zola J, et al. San Francisco hep B free: a ethnic differences, and viral interactions. Hepatology 2010;51:759–66.
grassroots community coalition to prevent hepatitis B and liver cancer. PMID:20140950 https://doi.org/10.1002/hep.23461
J Community Health 2011;36:538–51. PMID:21125320 https://doi. 64. Butt AA, Yan P, Aslam S, et al. Hepatitis C virologic response in
org/10.1007/s10900-010-9339-1 hepatitis B and C coinfected persons treated with directly acting antiviral
49. Lin SY, Chang ET, So SK. Stopping a silent killer in the underserved agents: Results from ERCHIVES. Int J Infect Dis 2020;92:184–8.
Asian and Pacific Islander community: a chronic hepatitis B and liver PMID:31978574 https://doi.org/10.1016/j.ijid.2020.01.025
cancer prevention clinic by medical students. Asian Pac J Cancer Prev 65. Harris AM, Millman AJ, Lora M, Osinubi A, Lom J, Miller LS.
2009;10:383–6. PMID:19640178 Hepatitis B testing, care linkage, and vaccination coverage within a
50. Haider M, Flocco G, Lopez R, Carey W. Retrospective observational registry of hepatitis C infected patients. Vaccine 2019;37:2188–93.
study of temporal trends and outcomes of hepatitis B screening in patients PMID:30902481 https://doi.org/10.1016/j.vaccine.2019.03.012
receiving rituximab. BMJ Open 2020;10:e043672. PMID:33323450 66. Hom JK, Kuncio D, Johnson CC, Viner K. Increased health and
https://doi.org/10.1136/bmjopen-2020-043672 social vulnerability among hepatitis C infected individuals co-infected
51. Harris AM, Osinubi A, Nelson NP, Thompson WW. The hepatitis B with hepatitis B. J Health Care Poor Underserved 2018;29:1269–80.
care cascade using administrative claims data, 2016. Am J Manag Care PMID:30449745 https://doi.org/10.1353/hpu.2018.0094
2020;26:331–8. PMID:32835460 https://doi.org/10.37765/ 67. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB.
ajmc.2020.44069 Prevalence and predictors of hepatitis B virus coinfection in a United
52. Spradling PR, Xing J, Rupp LB, et al.; Chronic Hepatitis Cohort States cohort of hepatitis C virus–infected patients. Hepatology
Study (CHeCS) Investigators. Infrequent clinical assessment of chronic 2013;58:538–45. PMID:23505059 https://doi.org/10.1002/hep.26400
hepatitis B patients in United States general healthcare settings. Clin 68. Kruse RL, Kramer JR, Tyson GL, et al. Clinical outcomes of hepatitis B
Infect Dis 2016;63:1205–8. PMID:27486115 https://doi.org/10.1093/ virus coinfection in a United States cohort of hepatitis C virus–infected
cid/ciw516 patients. Hepatology 2014;60:1871–8. PMID:25065513 https://doi.
53. Toy M, Wei B, Virdi TS, et al. Racial/ethnic- and county-specific org/10.1002/hep.27337
prevalence of chronic hepatitis B and its burden in California. Hepatol 69. Moorman AC, Xing J, Rupp LB, et al.; Chronic Hepatitis Cohort Study
Med Policy 2018;3:6. PMID:30288329 https://doi.org/10.1186/ Investigators. Hepatitis B virus infection and hepatitis C virus treatment
s41124-018-0034-7 in a large cohort of hepatitis C–infected patients in the United States.
54. Kim LH, Nguyen VG, Trinh HN, Li J, Zhang JQ, Nguyen MH. Low Gastroenterology 2018;154:754–8. PMID:29360428 https://doi.
treatment rates in patients meeting guideline criteria in diverse practice org/10.1053/j.gastro.2017.12.002
settings. Dig Dis Sci 2014;59:2091–9. PMID:25060778 https://doi.
org/10.1007/s10620-014-3283-3
22 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
70. Davison J, O’Shea A, Waterbury N, Villalvazo Y. Examining hepatitis A 85. CDC. Transmission of hepatitis B virus in correctional facilities—
and B vaccination, and HBV reactivation monitoring during direct-acting Georgia, January 1999–June 2002. MMWR Morb Mortal Wkly Rep
antiviral therapy for hepatitis C. J Community Health 2018;43:1124–7. 2004;53:678–81. PMID:15295311
PMID:29846860 https://doi.org/10.1007/s10900-018-0530-0 86. Custer B, Kessler DA, Vahidnia F, et al. Behavioral factors associated
71. Food and Drug Administration. FDA drug safety communication: with HIV, HBV, HCV, and HTLV infections in U.S. blood donors.
FDA warns about the risk of hepatitis B reactivating in some patients
Transfusion 2014;90:209A–10A.
treated with direct-acting antivirals for hepatitis C. Silver Spring,
MD: US Department of Health and Human Services, Food and 87. Kittikraisak W, Davidson PJ, Hahn JA, et al. Incarceration
Drug Administration; 2016. https://www.fda.gov/drugs/drug-safety- among young injectors in San Francisco: associations with risk for
and-availability/fda-drug-safety-communication-fda-warns-about- hepatitis C virus infection. J Subst Use 2006;11:271–81. https://doi.
risk-hepatitis-b-reactivating-some-patients-treated org/10.1080/14659890500420095
72. Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation 88. Marseille E, Harris AM, Horvath H, et al. Hepatitis B prevalence
during direct-acting antiviral therapy for hepatitis C: a systematic review association with sexually transmitted infections: a systematic review
and meta-analysis. Lancet Gastroenterol Hepatol 2018;3:172–80. and meta-analysis. Sex Health 2021;18:269–79. PMID:34183114
PMID:29371017 https://doi.org/10.1016/S2468-1253(18)30002-5 https://doi.org/10.1071/SH20185
73. Serper M, Forde KA, Kaplan DE. Rare clinically significant hepatic events 89. Roberts H, Jiles R, Harris AM, Gupta N, Teshale E. Incidence and
and hepatitis B reactivation occur more frequently following rather than
prevalence of sexually transmitted hepatitis B, United States, 2013–
during direct-acting antiviral therapy for chronic hepatitis C: data from
a national US cohort. J Viral Hepat 2018;25:187–97. PMID:28845882 2018. Sex Transm Dis 2021;48:305–9. PMID:33492099 https://doi.
https://doi.org/10.1111/jvh.12784 org/10.1097/OLQ.0000000000001359
74. Yanny BT, Latt NL, Saab S, et al. Risk of hepatitis B virus reactivation 90. Nelson NP, Jamieson DJ, Murphy TV. Prevention of perinatal hepatitis B
among patients treated with Ledipasvir-Sofosbuvir for hepatitis C virus virus transmission. J Pediatric Infect Dis Soc 2014;3(Suppl 1):S7–12.
infection. J Clin Gastroenterol 2018;52:908–12. PMID:29334502 PMID:25232477 https://doi.org/10.1093/jpids/piu064
https://doi.org/10.1097/MCG.0000000000000986 91. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally
75. Tong MJ, Theodoro CF, Salvo RT. Late development of hepatocellular transmitted hepatitis B virus infections with hepatitis B immune
carcinoma after viral clearance in patients with chronic hepatitis C: a need globulin and hepatitis B vaccine. Lancet 1983;2:1099–102.
for continual surveillance. J Dig Dis 2018;19:411–20. PMID:29889353 PMID:6138642 https://doi.org/10.1016/S0140-6736(83)90624-4
https://doi.org/10.1111/1751-2980.12615
92. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B
76. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR;
HALT-C Trial Group. Occult and previous hepatitis B virus infection immunisation in newborn infants of mothers positive for hepatitis B surface
are not associated with hepatocellular carcinoma in United States antigen: systematic review and meta-analysis. BMJ 2006;332:328–36.
patients with chronic hepatitis C. Hepatology 2011;54:434–42. PMID:16443611 https://doi.org/10.1136/bmj.38719.435833.7C
PMID:21374690 https://doi.org/10.1002/hep.24257 93. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of
77. Reddy A, May E, Ehrinpreis M, Mutchnick M. Latent hepatitis B is a risk hepatitis B and hepatitis C in people who inject drugs: results of
factor for hepatocellular carcinoma in patients with chronic hepatitis C. systematic reviews. Lancet 2011;378:571–83. PMID:21802134
World J Gastroenterol 2013;19:9328–33. PMID:24409059 https://doi. https://doi.org/10.1016/S0140-6736(11)61097-0
org/10.3748/wjg.v19.i48.9328 94. Ly KN, Xing J, Spradling PR. Trends in prevalence and characteristics
78. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of resolved and current hepatitis B among US-born persons: National
of HIV, hepatitis B virus, and hepatitis C virus infections among males
Health and Nutrition Examination Survey, 2001–2018. J Infect Dis
in Rhode Island prisons. Am J Public Health 2004;94:1218–23.
PMID:15226146 https://doi.org/10.2105/AJPH.94.7.1218 2021;224:804–12. PMID:33903902 https://doi.org/10.1093/infdis/
79. Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, jiab224
hepatitis B, and hepatitis C among entrants to Maryland correctional 95. Ganesan A, Krantz EM, Huppler Hullsiek K, et al.; Infectious
facilities. J Urban Health 2004;81:25–37. PMID:15047781 https://doi. Disease Clinical Research Program HIV/STI Working Group.
org/10.1093/jurban/jth085 Determinants of incident chronic kidney disease and progression in
80. Sosman J, Macgowan R, Margolis A, et al.; Project START Biologics a cohort of HIV-infected persons with unrestricted access to health
Study Group. Sexually transmitted infections and hepatitis in men care. HIV Med 2013;14:65–76. PMID:22808988 https://doi.
with a history of incarceration. Sex Transm Dis 2011;38:634–9. org/10.1111/j.1468-1293.2012.01036.x
PMID:21844713 https://doi.org/10.1097/OLQ.0b013e31820bc86c 96. Chun HM, Mesner O, Thio CL, et al.; Infectious Disease Clinical
81. Khan AJ, Simard EP, Bower WA, et al. Ongoing transmission of
Research Program HIV Working Group. HIV outcomes in hepatitis B
hepatitis B virus infection among inmates at a state correctional facility.
Am J Public Health 2005;95:1793–9. PMID:16186457 https://doi. virus coinfected individuals on HAART. J Acquir Immune Defic Syndr
org/10.2105/AJPH.2004.047753 2014;66:197–205. PMID:24694929 https://doi.org/10.1097/
82. Hennessey KA, Kim AA, Griffin V, Collins NT, Weinbaum CM, Sabin K. QAI.0000000000000142
Prevalence of infection with hepatitis B and C viruses and co-infection 97. Chun HM, Roediger MP, Hullsiek KH, et al.; Infectious Disease
with HIV in three jails: a case for viral hepatitis prevention in jails in Clinical Research Program HIV Working Group. Hepatitis B virus
the United States. J Urban Health 2009;86:93–105. PMID:18622707 coinfection negatively impacts HIV outcomes in HIV seroconverters.
https://doi.org/10.1007/s11524-008-9305-8 J Infect Dis 2012;205:185–93. PMID:22147794 https://doi.
83. CDC. Hepatitis B outbreak in a state correctional facility, 2000. MMWR org/10.1093/infdis/jir720
Morb Mortal Wkly Rep 2001;50:529–32. PMID:11446570 98. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT;
84. Lederman E, Blackwell A, Tomkus G, et al. Opt-out testing pilot
HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic
for sexually transmitted infections among immigrant detainees at
2 Immigration and Customs Enforcement Health Service Corps–staffed hepatitis B virus infection among patients in the HIV Outpatient Study,
detention facilities, 2018. Public Health Rep 2020;135(1_suppl):82S–9S. 1996–2007. J Viral Hepat 2010;17:879–86. PMID:20158604 https://
PMID:32735186 https://doi.org/10.1177/0033354920928491 doi.org/10.1111/j.1365-2893.2009.01249.x
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 23
Recommendations and Reports
99. Pitasi MA, Bingham TA, Sey EK, Smith AJ, Teshale EH. Hepatitis B 113. Moraras K, Block J, Shiroma N, Cannizzo A, Cohen C. Protecting the
virus (HBV) infection, immunity and susceptibility among men who rights of health care students living with hepatitis B under the Americans
have sex with men (MSM), Los Angeles County, USA. AIDS Behav with Disabilities Act. Public Health Rep 2020;135(1_suppl):13S–8S.
2014;18(Suppl 3):248–55. PMID:24276792 https://doi.org/10.1007/ PMID:32735187 https://doi.org/10.1177/0033354920921252
s10461-013-0670-2 114. Holmberg SD, Suryaprasad A, Ward JW; CDC. Updated CDC
100. Weinbaum CM, Lyerla R, Mackellar DA, et al.; Young Men’s recommendations for the management of hepatitis B virus–infected
Survey Study Group. The Young Men’s Survey phase II: hepatitis B health-care providers and students. MMWR Recomm Rep
immunization and infection among young men who have sex with 2012;61(No. RR-3):1–12. PMID:22763928
men. Am J Public Health 2008;98:839–45. PMID:18382012 https:// 115. Samuels J, Galanter S, Rodriguez L. Joint agency letter to health-
doi.org/10.2105/AJPH.2006.101915 related graduate schools regarding hepatitis B discrimination.
101. Burdick RA, Bragg-Gresham JL, Woods JD, et al. Patterns of Washington, DC: US Departments of Justice, Health and Human
hepatitis B prevalence and seroconversion in hemodialysis units Services, and Education; 2013. https://www.justice.gov/iso/opa/
from three continents: the DOPPS. Kidney Int 2003;63:2222–9. resources/732013612162552847322.pdf
PMID:12753311 https://doi.org/10.1046/j.1523-1755.2003.00017.x 116. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune
102. London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS. suppressive and biological modifier therapies: current concepts,
Host responses to hepatitis B infection in patients in a chronic management strategies, and future directions. Gastroenterology
hemodialysis unit. Kidney Int 1977;12:51–8. PMID:894916 https:// 2017;152:1297–309. PMID:28219691 https://doi.org/10.1053/j.
doi.org/10.1038/ki.1977.78 gastro.2017.02.009
103. Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B 117. Food and Drug Administration. FDA drug safety communication:
surface antigenemia (HBs Ag) in hemodialysis patients. Arch Intern boxed warning and new recommendations to decrease risk of
Med 1979;139:178–80. PMID:434972 https://doi.org/10.1001/ hepatitis B reactivation with the immune-suppressing and anti-cancer
archinte.1979.03630390036015 drugs Arzerra (ofatumumab) and Rituxan (rituximab). Silver Spring,
104. Alter MJ, Arduino MJ, Lyerla HC, Miller ER, Tokars JI. MD: US Department of Health and Human Services, Food and
Recommendations for preventing transmission of infections Drug Administration; 2016. https://www.fda.gov/drugs/drug-safety-
among chronic hemodialysis patients. MMWR Recomm Rep and-availability/fda-drug-safety-communication-boxed-warning-
2001;50(RR-5):1–43. PMID:11349873 and-new-recommendations-decrease-risk-hepatitis-b
105. Wang S, Cohen C, Tang AS, Graham CS. Hepatitis B virus elimination 118. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of
in the U.S.: time to dismantle barriers and implement solutions. preventive lamivudine on hepatitis B reactivation during chemotherapy.
Curr Hepatol Rep 2021;20:34–42. https://doi.org/10.1007/ Ann Intern Med 2008;148:519–28. PMID:18378948 https://doi.
s11901-020-00557-3 org/10.7326/0003-4819-148-7-200804010-00008
106. CDC. Screening for viral hepatitis during the domestic medical 119. Hourfar MK, Walch LA, Geusendam G, et al. Sensitivity and specificity
examination of newly arrived refugees. Atlanta, GA: US Department of anti-HBc screening assays—which assay is best for blood donor
of Health and Human Services, CDC; 2020. https://www.cdc.gov/ screening? Int J Lab Hematol 2009;31:649–56. PMID:18673399
immigrantrefugeehealth/guidelines/domestic/hepatitis-screening- https://doi.org/10.1111/j.1751-553X.2008.01092.x
guidelines.html 120. Gish RG, Basit SA, Ryan J, Dawood A, Protzer U. Hepatitis B
107. Title 21, Food and Drugs. 21 CFR §610.40 (2020). https:// core antibody: role in clinical practice in 2020. Curr Hepatol Rep
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. 2020;19:254–65. https://doi.org/10.1007/s11901-020-00522-0
cfm?FR=610.40 121. Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM; High Value
108. Myint A, Tong MJ, Beaven SW. Reactivation of hepatitis B virus: a Care Task Force of the American College of Physicians and the CDC.
review of clinical guidelines. Clin Liver Dis (Hoboken) 2020;15:162–7. Hepatitis B vaccination, screening, and linkage to care: best practice
PMID:32395244 https://doi.org/10.1002/cld.883 advice from the American College of Physicians and the Centers for
109. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening Disease Control and Prevention. Ann Intern Med 2017;167:794–804.
and management for patients with cancer prior to therapy: ASCO PMID:29159414 https://doi.org/10.7326/M17-1106
provisional clinical opinion update. J Clin Oncol 2020;38:3698–715. 122. Spradling PR, Xing J, Harris AM, Ly KN. Estimated prevalence and
PMID:32716741 https://doi.org/10.1200/JCO.20.01757 number of persons with isolated antibody to hepatitis B core antigen
110. Schillie S, Murphy TV, Sawyer M, et al.; CDC. CDC guidance for and associated occult hepatitis B, United States, 2001–2018. J Infect
evaluating health-care personnel for hepatitis B virus protection and Dis 2022;225:465–9. PMID:34252183 https://doi.org/10.1093/
for administering postexposure management. MMWR Recomm Rep infdis/jiab366
2013;62(No. RR-10):1–19. PMID:24352112 123. Council of State and Territorial Epidemiologists. Public health reporting
111. Daida YG, Boscarino JA, Moorman AC, et al.; Chronic Hepatitis and national notification for acute hepatitis B infections. 11-ID-03.
Cohort Study Investigators. Mental and physical health status among Atlanta, GA: Council of State and Territorial Epidemiologists; 2011.
chronic hepatitis B patients. Qual Life Res 2020;29:1567–77. https://cdn.ymaws.com/www.cste.org/resource/resmgr/PS/11-ID-03.pdf
PMID:31938963 https://doi.org/10.1007/s11136-020-02416-6 124. Council of State and Territorial Epidemiologists. Public health reporting
112. Tang A, Thornton K, Primary Care Workgroup HBV. Hepatitis B and national notification for chronic hepatitis B infections. 11-ID-04.
management: guidance for the primary care provider. Seattle, WA: Atlanta, GA: Council of State and Territorial Epidemiologists; 2011.
University of Washington, National Hepatitis Training Center; https://cdn.ymaws.com/www.cste.org/resource/resmgr/PS/11-ID-04.pdf
2020. https://www.hepatitisb.uw.edu/page/primary-care-workgroup/
guidance
24 MMWR / March 10, 2023 / Vol. 72 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention
Recommendations and Reports
125. CDC. Viral hepatitis surveillance and case management: guidance for 127. CDC. Planning and implementing screening and brief intervention
state, territorial, and local health departments. Atlanta, GA: CDC; for risky alcohol use: a step-by-step guide for primary care practices.
2021 https://www.cdc.gov/hepatitis/statistics/surveillanceguidance/ Atlanta, GA: CDC, National Center on Birth Defects and
docs/viral-hepatitis-surveillance-and-case-management_508.pdf Developmental Disabilities; 2014. https://www.cdc.gov/ncbddd/fasd/
126. Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services documents/AlcoholSBIImplementationGuide-P.pdf
Task Force. Screening for hepatitis B virus infection in adolescents and
adults: US Preventive Services Task Force recommendation statement.
JAMA 2020;324:2415–22. PMID:33320230 https://doi.org/10.1001/
jama.2020.22980
US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / March 10, 2023 / Vol. 72 / No. 1 25
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free
of charge in electronic format. To receive an electronic copy each week, visit MMWR at https://www.cdc.gov/mmwr/index.html.
Readers who have difficulty accessing this PDF file may access the HTML file at https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_
cid=rr7201a1_w. Address all inquiries about the MMWR Series to Editor-in-Chief, MMWR Series, Mailstop V25-5, CDC, 1600 Clifton Rd., N.E.,
Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.
All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations
or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses
listed in MMWR were current as of the date of publication.